Want to see DTIL full AI Analyst Report?
DTIL Stock Chart & Stats
$8.49
-$0.04(-0.55%)
At close: 4:00 PM EDT
$8.49
-$0.04(-0.55%)
Day’s Range― - ―
52-Week Range$3.53 - $9.62
Previous Close$7.51
Volume250.62K
Average Volume (3M)263.55K
Market Cap
$187.41M
Enterprise Value$143.79M
Total Cash (Recent Filing)$87.55M
Total Debt (Recent Filing)$28.10M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Nov 10, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.79
Shares Outstanding27,601,555
10 Day Avg. Volume246,296
30 Day Avg. Volume263,548
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.58
Price to Sales (P/S)1.56
P/FCF Ratio-0.81
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue3.19
Enterprise Value/Gross Profit3.19
Enterprise Value/Ebitda-2.89
Forecast
1Y Price Target
$45.00Price Target Upside430.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.59
Revenue Forecast (FY)$13.43M
Bulls Say, Bears Say
Bulls Say
ARCUS Gene-Editing PlatformA proprietary gene-editing platform gives Precision BioSciences a reusable foundation for multiple therapeutic programs rather than a single-asset business. Its focus on allogeneic therapies and genome-edited medicines may support broader development opportunities and durable strategic value if clinical programs advance.
DMD Clinical ExecutionDosing the first patient moves PBGENE-DMD from preclinical development into human testing, creating an important clinical validation opportunity. The program’s focus on restoring near full-length dystrophin could differentiate it from microdystrophin approaches if safety and efficacy data support the intended mechanism.
Low Debt BurdenA low absolute debt balance relative to equity limits near-term interest and refinancing pressure compared with a heavily leveraged biotechnology company. This provides some financial flexibility while Precision funds development, although it does not eliminate the need to manage its substantial operating cash consumption.
Bears Say
Substantial Cash BurnPersistent operating and free-cash-flow losses show that the business is consuming substantial cash to fund operations and development. If this pattern continues, Precision may need external capital, which can reduce financial flexibility and create funding pressure before clinical programs generate meaningful economic returns.
Unprofitable Core BusinessNegative net income, EBIT, and EBITDA indicate that the current operating model has not reached profitability. Continued losses constrain internally generated investment capacity and make future financial performance highly dependent on successful development outcomes, collaboration economics, or additional financing.
Volatile And Declining RevenueRecent revenue volatility and the sharp prior-year decline make the company’s revenue base difficult to rely on as a stable funding source. This weakens visibility into recurring operating support and increases the importance of milestone, collaboration, or other non-product revenue to sustain development.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.53 and its highest was $9.62 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $187.41M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Nov 10, 2026 which is in 12 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Aug 06, 2026. The company reported -$1.26 earnings per share for the quarter, missing the consensus estimate of -$0.804 by -$0.456.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.85.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 27,601,555 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$1.26 in its last earnings report, missing expectations of -$0.804. Following the earnings report the stock price went down -0.669%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precision BioSciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (430.04% Upside)
$45.00 (430.04% Upside)
Blogger Sentiment
Bullish
DTIL Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 27.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.43%
12-Months-Change
Fundamentals
Return on Equity
-91.60%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Precision BioSciences
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(430.04% Upside)
Technical Analysis
Ownership Overview
2.79% Insiders
5.06% Mutual Funds
0.16% Other Institutional Investors
83.12% Public Companies and
Individual Investors